Skip to main content
Log in

Comorbidities in patients with persistent or chronic immune thrombocytopenia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

There is a paucity of epidemiological data on the risk of comorbidities in adults with persistent or chronic immune thrombocytopenia (ITP). In this study, we compared the rates of cataracts, diabetes, renal failure, vascular events, lymphoma, and leukemia among patients with and without persistent or chronic ITP. Using administrative data, adult patients with medical claims for ITP from January, 2000 through September, 2006 were identified. An age- and gender-matched comparison cohort without evidence of ITP was randomly selected. The incidence rate ratio (IRR) of each comorbidity among ITP patients relative to the comparison group was estimated using Poisson regression, adjusting for baseline covariates. A total of 3,131 patients with persistent or chronic ITP were identified, and 9,392 were selected for the comparison cohort. The adjusted IRRs were as follows: diabetes 1.73 (95% CI 1.36–2.20), renal failure 2.05 (95% CI 1.67–2.51), any vascular event 1.70 (95% CI 1.41–2.05), lymphoma 5.91 (95% CI 2.61–13.37), leukemia 19.83 (95% CI 5.84–67.34), and mortality 4.21 (95% CI 3.06–5.79). There was no increased risk for cataract or myocardial infarction in the ITP cohort. Patients with persistent or chronic ITP are at increased risk for several comorbidities including hematologic malignancies, relative to a matched comparison cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.

    Article  CAS  PubMed  Google Scholar 

  2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008.

    Article  PubMed  Google Scholar 

  3. Satia J, Acquavella J, Hollowell J, Rutstein M. Descriptive epidemiology of immune thrombocytopenic purpura in three European countries. Haematologica. 2006;91(s1):0936 (Abstract Book).

    Google Scholar 

  4. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4:2377–83.

    Article  CAS  PubMed  Google Scholar 

  5. Deitz AC, Laurent SA, Kobayashi MG,Hall SA, Feudjo-Tepie MA. Prevalence estimate of idiopathic thrombocytopenic purpura (ITP) in the United States. Blood. 2006;108:3955 (Abstract Book).

    Google Scholar 

  6. Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost. 2008;6:711–2.

    Article  CAS  PubMed  Google Scholar 

  7. Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006;98:1321–30.

    Article  PubMed  Google Scholar 

  8. Feudjo-Tepie MA, Roux GL, Beach KJ, Bennett D, Robinson NJ. Comorbidities of idiopathic thrombocytopenic purpura: a population-based study. Adv Hematol. 2009;2009:963506, 12 pages. doi:10.1155/2009/963506.

  9. Feudjo-Tepie MA, Hall SA, Logie J, Robinson NJ. Risk of cataract among idiopathic thrombocytopenic purpura patients in the UK general practice research database. Pharmacoepidemiol Drug Saf. 2009;18:380–5.

    Article  PubMed  Google Scholar 

  10. Segal JB, Powe NR. Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study. Am J Hematol. 2004;75:12–7.

    Article  PubMed  Google Scholar 

  11. ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200–8.

    Google Scholar 

Download references

Acknowledgments

We thank Dr. Sumitra Shantakumar for helping to design the study and develop the protocol, and Ms. Claire Chiang MS for data analysis.

Conflict of interest

The authors declare no conflict of interest in the preparation of this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cheryl Enger.

About this article

Cite this article

Enger, C., Bennett, D., Forssen, U. et al. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol 92, 289–295 (2010). https://doi.org/10.1007/s12185-010-0636-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0636-3

Keywords

Navigation